Shares of Sagimet Biosciences Inc. (NASDAQ:SGMT – Get Free Report) crossed above its 50 day moving average during trading on Tuesday. The stock has a 50 day moving average of $9.94 and traded as high as $10.48. Sagimet Biosciences shares last traded at $10.42, with a volume of 1,108,685 shares.
Wall Street Analysts Forecast Growth
Several equities analysts have recently commented on SGMT shares. Guggenheim increased their price objective on Sagimet Biosciences from $25.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, October 2nd. Citizens Jmp dropped their target price on Sagimet Biosciences from $29.00 to $27.00 and set a “market outperform” rating for the company in a research report on Thursday, October 1st. HC Wainwright reaffirmed a “buy” rating and issued a $29.00 target price on shares of Sagimet Biosciences in a research note on Monday, October 5th. Citigroup reaffirmed a “market outperform” rating on shares of Sagimet Biosciences in a research note on Thursday, October 1st. Finally, Wall Street Zen cut shares of Sagimet Biosciences from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Nine research analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $26.63.
Sagimet Biosciences Price Performance
Sagimet Biosciences (NASDAQ:SGMT – Get Free Report) last released its earnings results on Tuesday, August 11th. The company reported ($0.26) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.25) by ($0.01). Research analysts predict that Sagimet Biosciences Inc. will post -1.14 earnings per share for the current fiscal year.
Insider Buying and Selling
In other Sagimet Biosciences news, Director George Kemble sold 20,206 shares of the business’s stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $9.95, for a total value of $201,049.70. Following the completion of the sale, the director owned 62,161 shares in the company, valued at approximately $618,501.95. The trade was a 24.53% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 11.50% of the stock is owned by company insiders.
Institutional Trading of Sagimet Biosciences
Institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP raised its holdings in Sagimet Biosciences by 99.4% during the 1st quarter. Dimensional Fund Advisors LP now owns 271,217 shares of the company’s stock valued at $1,415,000 after buying an additional 135,178 shares during the last quarter. Seven Fleet Capital Management LP purchased a new stake in Sagimet Biosciences during the 2nd quarter valued at $3,119,000. Bank of New York Mellon Corp bought a new stake in Sagimet Biosciences in the 2nd quarter worth $1,551,000. Renaissance Technologies LLC grew its holdings in Sagimet Biosciences by 82.6% in the 1st quarter. Renaissance Technologies LLC now owns 625,469 shares of the company’s stock worth $3,268,000 after acquiring an additional 282,969 shares during the last quarter. Finally, AWM Investment Company Inc. bought a new stake in Sagimet Biosciences in the 2nd quarter worth $618,000. Hedge funds and other institutional investors own 87.86% of the company’s stock.
About Sagimet Biosciences
Sagimet Biosciences, Inc (NASDAQ:SGMT) is a clinical-stage biopharmaceutical company developing therapies that target fatty acid synthase (FASN), an enzyme involved in the production of fatty acids. The company is focused on using FASN inhibition to address metabolic, inflammatory and oncological diseases for which additional treatment options are needed.
Sagimet’s lead investigational product is denifanstat, an orally administered, selective FASN inhibitor formerly known as TVB-2640. The company has primarily advanced denifanstat as a potential treatment for metabolic dysfunction-associated steatohepatitis (MASH), a chronic liver disease associated with liver inflammation and fibrosis.
Further Reading
- Five stocks we like better than Sagimet Biosciences
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Sagimet Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sagimet Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.
